Ifinatamab Deruxtecan Earns FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer

4 weeks ago 20

The FDA has granted breakthrough therapy designation to ifinatamab deruxtecan for the treatment of patients with extensive-stage small cell lung cancer.

1. Homepage
2. Lung Cancer
3. Ifinatamab Deruxtecan Earns FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer